Chad Hatfield, Pharm.D., M.H.A., BCPS, vice president and chief pharmacy officer of UC Davis Health, says pharmacists are embedded in “nearly all specialties," with more than 150 holding board certification.
|Podcasts|December 9, 2020
Addressing SDoH During, After COVID-19 per Manik Bhat of Healthify
Author(s)Briana Contreras
Briana Contreras of MHE spoke with Manik Bhat, founder and CEO of Healthify – a company that works with managed care organizations to integrate social determinants of health (SDoH) into the healthcare ecosystem. Manik and Briana spoke about how the need to address SDoH has changed since the COVID-19 pandemic began and what the importance of addressing these social and economic issues are during and after the pandemic. They also touched on how SDoH contribute to the spread of viral diseases, but worsen the issues for individuals already struggling.
Advertisement
To listen to more episodes featured on Tuning Into The C-Suite, visit us on Spotify , Apple Podcasts and iHeartRadio .
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
8-year data show adjuvant Tagrisso boosts survival after surgery for EGFR-mutated NSCLC, reshaping early Lung Cancer care and adherence.
Sova, a clinical advisor for Employers Health, expects more employers to exclude GLP-1s for obesity but urges a look at coverage for specific cardiometabolic conditions.
Employers Health’s Alexis Sova says employers excluding GLP-1s now lean on weight management programs and direct-to-employer deals, not a hard cutoff.
Approximately two-thirds of Employers Health clients now exclude GLP-1s for obesity, up from a roughly even split at launch as cost drives coverage decisions.
Chad Hatfield, Pharm.D., MHA, BCPS, of UC Davis Health, discusses the system's pharmacy shared service center, embedded pharmacists and 340B rebate readiness.
Blood tests reveal early, widespread inflammation in hidradenitis suppurativa, linking biomarkers to disease severity, quality of life, smoking, and potential cardiovascular risk.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Systemic inflammation present even in mild hidradenitis suppurativa
2
Large study finds GLP-1 drugs may lower fracture risk in Type 2 diabetes
3
Alexis Sova, Pharm.D., MBA, on where GLP-1 coverage goes next | PBMI 2026
4
Alexis Sova, Pharm.D., MBA, on GLP-1 access when coverage ends | PBMI 2026
5